{'fraction_non_alphanumeric': 0.021604938271604937, 'fraction_numerical': 0.004629629629629629, 'mean_word_length': 5.790575916230367, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Metabolic monitoring in commercially insured pediatric patients newly initiated to take a second-generation antipsychotic.

Metabolic Monitoring in Commercially Insured Pediatric Patients Newly Initiated to Take a Second-Generation Antipsychotic The use of second-generation antipsychotics (SGAs) in children and adolescents has increased amidst the concern for adverse effects (AEs) on overall health. The use of SGAs increases the risk for weight gain, elevated glucose, insulin resistance, hyperlipidemia, and development of type 2 diabetes mellitus.1,2 Despite these concerns, there has been a slow uptake performing recommended monitoring.3-6 To our knowledge, few studies have examined metabolic monitoring in pediatric patients receiving an SGA, most of which were conducted in Medicaid patients.6 As Medicaid beneficiaries are expected to be financially poorer, have a poorer health profile, and receive care in a fragmented system of services compared with the commercially insured, it is important to understand metabolic monitoring practices in non-Medicaid patient populations. The purpose of this study was to evaluate metabolic monitoring practices for commercially insured pediatric patients newly initiated to take an SGA and identify metabolic AEs associated with short-term use.